The regulatory green light follows findings from the PROTECT study, which demonstrated that the drug effectively preserves beta cell function in newly diagnosed individuals. By intervening within eight weeks of a stage 3 diagnosis, clinicians can now offer a therapeutic option for patients whose bodies can no longer produce sufficient insulin. Tzield previously gained approval in 2022 for stage 2 patients, establishing it as the only disease-modifying treatment currently available for the autoimmune condition.

Breakthrough T1D CEO Aaron J. Kowalski described the decision as a milestone in diabetes care. While the current approval addresses a specific age bracket, ongoing research continues through Sanofi’s BETA-PRESERVE study to further evaluate long-term outcomes. This expansion also sets a regulatory precedent for future therapies utilizing C-peptide levels as a primary clinical trial endpoint, potentially accelerating the development of additional treatments for the 9.5 million people living with type 1 diabetes globally.